Chemoprevention of lung pathologies by dietary n-3 polyunsaturated fatty acids

Current Medicinal Chemistry

Volumn 17, Issue 29, 2010, Pages 3358-3376

  Fasano, E ^a   Serini, S ^a   Piccioni, E ^a   Calviello, G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

ALI; ARDS; Asthma; Cancer; COPD; Cystic fibrosis; Interstitial lung diseases; Lung; n 3 PUFAs

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; ICOSANOID; ICOSAPENTAENOIC ACID; POLYUNSATURATED FATTY ACID;

ACUTE LUNG INJURY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CHEMOPROPHYLAXIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DIET SUPPLEMENTATION; DIETARY INTAKE; GENE EXPRESSION; INTERSTITIAL LUNG DISEASE; LUNG CANCER; LUNG DISEASE; LUNG FUNCTION; PATHOGENESIS; PNEUMONIA; RESPIRATORY DISTRESS;

EID: 77957935855     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710793176401     Document Type: Article

References (237)

1. Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin., 2005, 55, 74-108.
2. Gordon, E.; Lazarus, S.C. Management of chronic obstructive pulmonary disease: moving beyond the asthma algorithm. J. Allergy Clin. Immunol., 2009, 124, 873-880.
3. Camoretti-Mercado, B. Targeting the airway smooth muscle for asthma treatment. Transl. Res., 2009, 154, 165-174.
4. Bailey, W.C.; Tashkin, D.P. Pharmacologic therapy: novel approaches for chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc., 2007, 4, 543-548.
5. Caramori, G.; Adcock, I. Pharmacology of airway inflammation in asthma and COPD. Pulm. Pharmacol. Ther., 2003, 16, 247-277.
6. Séguin, R.M.; Ferrari, N. Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease. Expert Opin. Investig. Drugs, 2009, 18, 1505-1517.
7. Serini, S.; Piccioni, E.; Rinaldi, C.; Mostra, D.; Damiani, G.; Calviello, G. Fish from an artificial lake: n-3 PUFA content and chemical-physical and ecological features of the lake. J. Food Compos. Anal., 2010, 23, 133-141.
8. Calzolari, I.; Fumagalli, S.; Marchionni, N.; Di Bari, M. Polyunsaturated fatty acids and cardiovascular disease. Curr. Pharm. Des., 2009, 15, 4094-4102.
9. Lee, J.H.; O'Keefe, J.H.; Lavie, C.J.; Harris, W.S. Omega-3 fatty acids: cardiovascular benefits, sources and sustainability. Nat. Rev. Cardiol., 2009, 6, 753-758.
10. Berquin, I.M.; Edwards, I.J.; Chen, Y.Q. Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer Lett., 2008, 269, 363-377.
11. Calviello, G.; Serini, S.; Piccioni, E.; Pessina, G. Antineoplastic effects of n-3 polyunsaturated fatty acids in combination with drugs and radiotherapy: preventive and therapeutic strategies. Nutr. Cancer, 2009, 61, 287-301.
12. Kromann, N.; Green, A. Epidemiological studies in the Upernavik district, Greenland. Incidence of some chronic diseases 1950-1974. Acta Med. Scand., 1980, 208, 401-406.
13. Schwartz, J.; Weiss, S.T. Dietary factors and their relation to respiratory symptoms. The Second National Health and Nutrition Examination Survey. Am. J. Epidemiol., 1990, 132, 67-76.
14. Schwartz, J.; Weiss, S.T. The relationship of dietary fish intake to level of pulmonary function in the first National Health and Nutrition Survey (NHANES I) Eur. Respir. J., 1994, 7, 1821-1824.
15. Sharp, D.S.; Rodriguez, B.L.; Shahar, E.; Hwang, L.J.; Burchfiel, C.M. Fish consumption may limit the damage of smoking on the lung. Am. J. Respir. Crit. Care Med., 1994, 150, 983-987.
16. Burdge, G.C.; Lupoli, B.; Russell, J.J.; Tricon, S.; Kew, S.; Banerjee, T.; Shingfield, K.J.; Beever, D.E.; Grimble, R.F.; Williams, C.M.; Yaqoob, P.; Calder, P.C. Incorporation of cis-9,trans-11 or trans-10,cis-12 conjugated linoleic acid into plasma and cellular lipids in healthy men. J. Lipid Res., 2004, 45, 736-741.
17. Brenna, J.T.; Salem, N. Jr.; Sinclair, A.J.; Cunnane, S.C.; International Society for the Study of Fatty Acids and Lipids, ISSFAL. alpha-Linolenic acid supplementation and conversion to n-3 longchain polyunsaturated fatty acids in humans. Prostaglandins Leukot. Essent. Fatty Acids, 2009, 80, 85-91.
18. Schmitz, G.; Ecker J. The opposing effects of n-3 a nd n-6 fatty acids. Prog. Lipid Res., 2008, 47, 147-155.
19. Simopoulos, A.P. Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implications for chronic diseases. Biomed. Pharmacother., 2006, 60, 502-507.
20. Simopoulos, A.P. Omega-3 fatty acids in health and disease and in growth and development. Am. J. Clin. Nutr., 1991, 54, 438-463.
21. Yeh, L.L.; Kuller, L.H.; Bunker, C.H.; Ukoli, F.A.; Huston, S.L.; Terrell, D.F. The role of socioeconomic status and serum fatty acids in the relationship between intake of animal foods and cardiovascular risk factors. Ann. Epidemiol., 1996, 6, 290-298.
22. Sessler, A.M.; Ntambi, J.M. Polyunsaturated fatty acid regulation of gene expression. J. Nutr., 1998, 128, 923-926.
23. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 1995, 152, S77-S121.
24. Barnes, P.J. Chronic obstructive pulmonary disease. N. Engl. J. Med., 2000, 343, 269-280.
25. Salvi, S.S.; Barnes, P.J. Chronic obstructive pulmonary disease in non-smokers. Lancet, 2009, 374, 733-743.
26. Barnes, P.J. Genetics and pulmonary medicine. 9. Molecular genetics of chronic obstructive pulmonary disease. Thorax, 1999, 54, 245-252.
27. Wan, E.S.; Silverman, E.K. Genetics of COPD and emphysema. Chest, 2009, 136, 859-866.
28. Barnes, P.J. The cytokine network in chronic obstructive pulmonary disease. Am. J. Respir. Cell. Mol. Biol., 2009, 41, 631-638.
29. MacNee, W.; Tuder, R.M. New paradigms in the pathogenesis of chronic obstructive pulmonary disease I. Proc. Am. Thorac. Soc., 2009, 6, 527-531.
30. Leaver, S.K.; Evans, T.W. Acute respiratory distress syndrome. BMJ., 2007, 335, 389-394.
31. Piantadosi, C.A.; Schwartz, D.A. The acute respiratory distress syndrome. Ann. Intern. Med., 2004, 141, 460-470.
32. Wheeler, A.P.; Bernard, G.R. Acute lung injury and the acute respiratory distress syndrome: a clinical review. Lancet, 2007, 369, 1553-1564.
33. Rubenfeld, G.D.; Caldwell, E.; Peabody, E.; Weaver, J.; Martin, D.P.; Neff, M.; Stern, E.J.; Hudson, L.D. Incidence and outcomes of acute lung injury. N. Engl. J. Med., 2005, 353, 1685-1693.
34. Ware, L.B.; Matthay, M.A. The acute respiratory distress syndrome. N. Engl. J. Med., 2000, 342, 1334-1349.
35. Bellingan, G.J. The pulmonary physician in critical care * 6: The pathogenesis of ALI/ARDS. Thorax, 2002, 57, 540-546.
36. Dos Santos, C.C. Advances in mechanisms of repair and remodelling in acute lung injury. Intensive Care Med., 2008, 34, 619-630.
37. Singer P, Shapiro H. Enteral omega-3 in acute respiratory distress syndrome. Curr. Opin. Clin. Nutr. Metab. Care, 2009, 12, 123-128.
38. O'Sullivan, B.P.; Freedman, S.D. Cystic fibrosis. Lancet, 2009, 373, 1891-1904.
39. Hanrahan, J.W.; Wioland, M.A. Revisiting cystic fibrosis transmembrane conductance regulator structure and function. Proc. Am. Thorac. Soc., 2004, 1, 17-21.
40. Anonymous. The Cystic Fibrosis Genotype-Phenotype Consortium: correlation between genotype and phenotype in patients with cystic fibrosis. N. Engl. J. Med., 1993, 329, 1308-1313.
41. Gibson, R.L.; Burns, J.L.; Ramsey, B.W. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am. J. Respir. Crit. Care Med., 2003, 168, 918-951.
42. Machen, T.E. Innate immune response in CF airway epithelia: hyperinflammatory? Am. J. Physiol. Cell Physiol., 2006, 291, C218-C230.
43. Al-Turkmani, M.R.; Andersson, C.; Alturkmani, R.; Katrangi, W.; Cluette-Brown, J.E.; Freedman, S.D.; Laposata, M. A mechanism accounting for the low cellular level of linoleic acid in cystic fibrosis and its reversal by DHA. J. Lipid Res., 2008, 49, 1946-1954.
44. Busse, W.W., Lemanske, R.F. Jr. Asthma. N. Engl. J. Med., 2001, 344, 350-362.
45. Anderson, G.P. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet, 2008, 372, 1107-1119.
46. Vercelli, D. Discovering susceptibility genes for asthma and allergy. Nat. Rev. Immunol., 2008, 8, 169-182.
47. Eder, W.; Ege, M.J.; von Mutius, E. The asthma epidemic. N. Engl. J. Med., 2006, 355, 2226-2235.
48. Woodruff, P.G.; Fahy, J.V. Asthma: prevalence, pathogenesis, and prospects for novel therapies. JAMA, 2001, 286, 395-398.
49. Barnes, P.J. The cytokine network in asthma and chronic obstructive pulmonary disease. J. Clin. Invest., 2008, 118, 3546-3556.
50. Barnes, P.J. Immunology of asthma and chronic obstructive pulmonary disease. Nat. Rev. Immunol., 2008, 8, 183-192.
51. Strachan, D.P. Hay fever, hygiene, and household size. BMJ, 1989, 299, 1259-1260.
52. Strachan, D.P. Family size, infection and atopy: the first decade of the hygiene hypothesis. Thorax, 2000, 55, S2-S10.
53. Robinson, D.S. Regulatory T cells and asthma. Clin. Exp. Allergy, 2009, 39, 1314-1323.
54. Louten, J.; Boniface, K.; de Waal Malefyt, R. Development and function of TH17 cells in health and disease. J. Allergy Clin. Immunol., 2009, 123, 1004-1011.
55. Charbeneau, R.P.; Peters-Golden, M. Eicosanoids: mediators and therapeutic targets in fibrotic lung disease. Clin. Sci. (Lond)., 2005, 108, 479-491.
56. Kanaoka, Y.; Boyce, J.A. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J. Immunol., 2004, 173, 1503-1510.
57. Kowal-Bielecka, O.; Kowal, K.; Distler, O.; Gay, S. Mechanisms of Disease: leukotrienes and lipoxins in scleroderma lung disease--insights and potential therapeutic implications. Nat. Clin. Pract. Rheumatol., 2007, 3, 43-51.
58. Huang, S.K.; Peters-Golden, M. Eicosanoid lipid mediators in fibrotic lung diseases: ready for prime time? Chest, 2008, 133, 1442-1450.
59. Calder, P.C. Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Mol. Nutr. Food Res., 2008, 52, 885-897.
60. Lewis, R. A.; Austen, K. F.; Soberman, R. J. Leukotrienes and other products of the 5-lipoxygenase pathway: Biochemistry and relation to pathobiology in human diseases. N. Eng. J. Med., 1990, 323, 645-655.
61. Tilley, S. L., Coffman, T. M., Koller, B. H., Mixed messages: Modulation of inflammation and immune responses by prostaglandins and thromboxanes. J. Clin. Invest., 2001, 108, 15-23.
62. Calder, P.C. Polyunsaturated fatty acids and inflammatory processes: New twists in an old tale. Biochimie, 2009, 91, 791-795.
63. Chapkin, R.S.; Kim, W.; Lupton, J.R.; McMurray, D.N. Dietary docosahexaenoic and eicosapentaenoic acid: emerging mediators of inflammation. Prostaglandins Leukot. Essent. Fatty Acids, 2009, 81, 187-191.
64. Kliewer, S.A.; Sundseth, S.S.; Jones, S.A.; Brown, P.J.; Wisely, G.B.; Koble, C.S.; Devchand, P.; Wahli, W.; Willson, T.M.; Lenhard, J.M.; Lehmann, J.M. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc. Natl. Acad. Sci. U.S.A., 1997, 94, 4318-4323.
65. Mayer, K.; Kiessling, A.; Ott, J.; Schaefer, M.B.; Hecker, M.; Henneke, I.; Schulz, R.; Günther, A.; Wang, J.; Wu, L.; Roth, J.; Seeger, W.; Kang, J.X. Acute lung injury is reduced in fat-1 mice endogenously synthesizing n-3 fatty acids. Am. J. Respir. Crit. Care Med., 2009, 179, 474-483.
66. Kang, J.X. Fat-1 transgenic mice: a new model for omega-3 research. Prostaglandins Leukot. Essent. Fatty Acids, 2007, 77, 263-267.
67. Zhao, Y.; Chen, L.H. Eicosapentaenoic acid prevents lipopolysac-charide-stimulated DNA binding of activator protein-1 and c-Jun N-terminal kinase activity. Nutr. Biochem., 2005, 16, 78-84.
68. Li, H.; Ruan, X.Z.; Powis, S.H.; Fernando, R.; Mon, W.Y.; Wheeler, D.C.; Moorhead, J.F.; Varghese, Z. EPA and DHA reduce LPS-induced inflammation responses in HK-2 cells: EPA and DHA reduce LPS-induced inflammation responses in HK-2 cells: evidence for a PPAR-gamma-dependent mechanism. Kidney Int., 2005, 67, 867-874.
69. Marion-Letellier, R.; Butler, M.; Déchelotte, P.; Playford, R.J.; Ghosh, S. Comparison of cytokine modulation by natural peroxisome proliferator-activated receptor gamma ligands with synthetic ligands in intestinal-like Caco-2 cells and human dendritic cells--potential for dietary modulation of peroxisome proliferator-activated receptor gamma in intestinal inflammation. Am. J. Clin. Nutr., 2008, 87, 939-948.
70. Ricote, M.; Glass, C.K. PPARs and molecular mechanisms of transrepression. Biochim. Biophys. Acta, 2007, 1771, 926-935.
71. Kobayashi, M.; Thomassen, M.J.; Rambasek, T.; Bonfield, T.L.; Raychaudhuri, B.; Malur, A.; Winkler, A.R.; Barna, B.P.; Goldman, S.J.; Kavuru, M.S. An inverse relationship between peroxisome proliferator-activated receptor gamma and allergic airway inflammation in an allergen challenge model. Ann. Allergy Asthma Immunol., 2005, 95, 468-473.
72. Woerly, G.; Honda, K.; Loyens, M.; Papin, J.P.; Auwerx, J.; Staels, B.; Capron, M.; Dombrowicz, D. Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation. J. Exp. Med., 2003, 198, 411-421.
73. Hammad, H.; de Heer, H.J.; Soullié, T.; Angeli, V.; Trottein, F.; Hoogsteden, H.C.; Lambrecht, B.N. Activation of peroxisome proliferator-activated receptor-gamma in dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthma. Am. J. Pathol., 2004, 164, 263-271.
74. Malur, A.; Mccoy, A.J.; Arce, S.; Barna, B.P.; Kavuru, M.S.; Malur, A.G.; Thomassen, M.J. Deletion of PPAR gamma in alveolar macrophages is associated with a Th-1 pulmonary inflammatory response. J. Immunol., 2009, 182, 5816-5822.
75. Sharma, R.; Kaundal, R.K.; Sharma, S.S. Amelioration of pulmonary dysfunction and neutrophilic inflammation by PPAR gamma agonist in LPS-exposed guinea pigs. Pulm. Pharmacol. Ther., 2009, 22, 183-189.
76. Andersson, C.; Zaman, M.M.; Jones, A.B.; Freedman, S.D. Alterations in immune response and PPAR/LXR regulation in cystic fibrosis macrophages. J. Cyst. Fibros., 2008, 7, 68-78.
77. Serhan CN. Systems approach to inflammation resolution: identification of novel anti-inflammatory and pro-resolving mediators. J. Thromb. Haemost., 2009, 7, 44-48.
78. Planaguma, A.; Levy, B.D. Uncontrolled airway inflammation in lung disease represents a defect in counter-regulatory signaling. Future Lipidol., 2008, 3, 697-704.
79. Serhan, C.N.; Chiang, N. Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br. J. Pharmacol., 2008, 153, S200-S215.
80. Levy, B.D.; Kohli, P.; Gotlinger, K.; Haworth, O.; Hong, S.; Kazani, S.; Israel, E.; Haley, K.J.; Serhan, C.N. Protectin D1 is generated in asthma and dampens airway inflammation and hyperrespon-siveness. J. Immunol., 2007, 178, 496-502.
81. Aoki, H.; Hisada, T.; Ishizuka, T.; Utsugi, M.; Kawata, T.; Shimizu, Y.; Okajima, F.; Dobashi, K.; Mori, M. Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma. Biochem. Biophys. Res. Commun., 2008, 367, 509-515.
82. Haworth, O.; Cernadas, M.; Yang, R.; Serhan, C.N.; Levy, B.D. Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat. Immunol., 2008, 9, 873-879.
83. Seki, H.; Fukunaga, K.; Arita, M.; Arai, H.; Nakanishi, H.; Taguchi, R.; Miyasho, T.; Takamiya, R.; Asano, K.; Ishizaka, A.; Takeda, J.; Levy, B.D. The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury. J. Immunol., 2010, 184, 836-843.
84. Aoki, M. Epidemiology of chronic airways diseases in Japan. Chest, 1989, 96, 343S-349S.
85. Comstock, G.W.; Stone, R.W.; Sakai, Y.; Matsuya, T.; Tonascia, J.A. Respiratory findings and urban living. Arch. Environ. Health, 1973, 27, 143-150.
86. Ohsawa, M.; Itai, K.; Onoda, T.; Tanno, K.; Sasaki, S.; Nakamura, M.; Ogawa, A.; Sakata, K.; Kawamura, K.; Kuribayashi, T.; Yoshida, Y.; Okayama, A. Dietary intake of n-3 polyunsaturated fatty acids is inversely associated with CRP levels, especially among male smokers. Atherosclerosis, 2008, 201, 184-191.
87. Shahar, E.; Folsom, A.R.; Melnick, S.L.; Tockman, M.S.; Comstock, G.W.; Gennaro, V.; Higgins, M.W.; Sorlie, P.D.; Ko, W.J.; Szklo, M. Dietary n-3 polyunsaturated fatty acids and smokingrelated chronic obstructive pulmonary disease. Atherosclerosis Risk in Communities Study Investigators. N. Engl. J. Med., 1994, 331, 228-233.
88. Shahar, E.; Boland, L.L.; Folsom, A.R.; Tockman, M.S.; McGovern, P.G.; Eckfeldt, J.H. Docosahexaenoic acid and smoking-related chronic obstructive pulmonary disease. The Atherosclerosis Risk in Communities Study Investigators. Am. J. Respir. Crit. Care Med., 1999, 159,1780-1785.
89. Kompauer, I.; Demmelmair, H.; Koletzko, B.; Bolte, G.; Linseisen, J.; Heinrich, J. Association of fatty acids in serum phospholipids with lung function and bronchial hyperresponsiveness in adults. Eur. J. Epidemiol., 2008, 23, 175-190.
90. Miedema, I.; Feskens, E.J.; Heederik, D.; Kromhout, D. Dietary determinants of long-term incidence of chronic nonspecific lung diseases. The Zutphen Study. Am. J. Epidemiol., 1993, 138, 37-45.
91. McKeever, T.M.; Lewis, S.A.; Cassano, P.A.; Ocké, M.; Burney, P.; Britton, J.; Smit, H.A. The relation between dietary intake of individual fatty acids, FEV1 and respiratory disease in Dutch adults. Thorax, 2008, 63, 208-214.
92. Twisk, J.W.; Staal, B.J.; Brinkman, M.N.; Kemper, H.C.; van Mechelen, W. Tracking of lung function parameters and the longitudinal relationship with lifestyle. Eur. Respir. J., 1998, 12, 627-634.
93. Butland, B.K.; Fehily, A.M.; Elwood, P.C. Diet, lung function, and lung function decline in a cohort of 2512 middle aged men. Thorax, 2000, 55, 102-108.
94. Broekhuizen, R.; Wouters, E.F.; Creutzberg, E.C.; Weling-Scheepers, C.A.; Schols, A.M. Polyunsaturated fatty acids improve exercise capacity in chronic obstructive pulmonary disease. Thorax, 2005, 60, 376-382.
95. Keller, H.; Dreyer, C.; Medin, J.; Mahfoudi, A.; Ozato, K.; Wahli, W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc. Natl. Acad. Sci. U.S.A., 1993, 90, 2160-2164.
96. Schoonjans, K.; Peinado-Onsurbe, J.; Lefebvre, A.M.; Heyman, R.A.; Briggs, M.; Deeb, S.; Staels, B.; Auwerx, J. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J., 1996, 15, 5336-5348.
97. Gulick, T.; Cresci, S.; Caira, T.; Moore, D.D.; Kelly, D.P. The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc. Natl. Acad. Sci. U.S.A., 1994, 91, 11012-11016.
98. Asada, K.; Sasaki, S.; Suda, T.; Chida, K.; Nakamura, H. Antiinflammatory roles of peroxisome proliferator-activated receptor gamma in human alveolar macrophages. Am. J. Respir. Crit. Care Med., 2004, 169, 195-200.
99. Mayer, K.; Seeger, W. Fish oil in critical illness. Curr. Opin. Clin. Nutr. Metab. Care, 2008, 11, 121-127.
100. Masclans, J.R.; Sabater, J.; Sacanell, J.; Chacon, P.; Sabin, P.; Roca O., Planas M. Possible prognostic value of leukotriene B(4) in acute respiratory distress syndrome. Respir. Care, 2007, 52, 1695-1700.
101. Zarbock, A.; Singbartl, K.; Ley, K. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J. Clin. Invest., 2006, 116, 3211-3219.
102. Sane, S.; Baba, M.; Kusano, C.; Shirao, K.; Andoh, T.; Kamada, T.; Aikou, T. Eicosapentaenoic acid reduces pulmonary edema in endotoxemic rats. J. Surg. Res., 2000, 93, 21-27.
103. Mancuso, P.; Whelan, J.; DeMichele, S.J.; Snider, C.C.; Guszcza, J.A.; Claycombe, K.J.; Smith, G.T.; Gregory, T.J.; Karlstad, M.D. Effects of eicosapentaenoic and gamma-linolenic acid on lung permeability and alveolar macrophage eicosanoid synthesis in endotoxic rats. Crit. Care Med., 1997, 25, 523-532.
104. Mancuso, P.; Whelan, J.; DeMichele, S.J.; Snider, C.C.; Guszcza, J.A.; Karlstad, M.D. Dietary fish oil and fish and borage oil suppress intrapulmonary proinflammatory eicosanoid biosynthesis and attenuate pulmonary neutrophil accumulation in endotoxic rats. Crit. Care Med., 1997, 25, 1198-1206.
105. Murray, M.J.; Kumar, M.; Gregory, T.J.; Banks, P.L.; Tazelaar, H.D.; DeMichele, S.J. Select dietary fatty acids attenuate cardio-pulmonary dysfunction during acute lung injury in pigs. Am. J. Physiol., 1995, 269, H2090-H2099.
106. Montejo, J.C.; Zarazaga, A.; López-Martínez, J.; Urrútia, G.; Roqué, M.; Blesa, A.L.; Celaya, S.; Conejero, R.; Galbán, C.; García de Lorenzo, A.; Grau, T.; Mesejo, A.; Ortiz-Leyba, C.; Planas, M.; Ordóñez, J.; Jiménez, F.J.; Spanish Society of Intensive Care Medicine and Coronary Units. Immunonutrition in the intensive care unit. A systematic review and consensus statement. Clin. Nutr., 2003, 22, 221-233.
107. Marik, P.E.; Zaloga, G.P. Immunonutrition in critically ill patients: a systematic review and analysis of the literature. Intens. Care Med., 2008, 34, 1980-1990.
108. Heyland, D.; Dhaliwal, R. Immunonutrition in the critically ill: from old approaches to new paradigms. Intens. Care Med., 2005, 31, 501-503.
109. rd.;Spur, B.W.; Robinson, D.R.; Corey, E.J.; Lewis, R.A.; Austen, K.F. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N. Engl. J. Med., 1985, 312, 121712-121724.
110. Kapoor, R.; Huang, Y.S. Gamma linolenic acid: an antiinflammatory omega-6 fatty acid. Curr. Pharm. Biotechnol., 2006, 7, 531-534.
111. Mayes, T.; Gottschlich, M.M.; Kagan, R.J. An evaluation of the safety and efficacy of an anti-inflammatory, pulmonary enteral formula in the treatment of pediatric burn patients with respiratory failure. J. Burn Care Res., 2008, 29, 82-88.
112. Singer, P.; Theilla, M.; Fisher, H.; Gibstein, L.; Grozovski, E.; Cohen, J. Benefit of an enteral diet enriched with eicosapentaenoic acid and gamma-linolenic acid in ventilated patients with acute lung injury. Crit. Care Med., 2006, 34, 1033-1038.
113. Gadek, J.E.; DeMichele, S.J.; Karlstad, M.D.; Pacht, E.R.; Donahoe, M.; Albertson, T.E.; Van Hoozen, C.; Wennberg, A.K.; Nelson, J.L.; Noursalehi, M. Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Enteral Nutrition in ARDS Study Group. Crit. Care Med., 1999, 27, 1409-1420.
114. Pacht, E.R.; DeMichele, S.J.; Nelson, J.L.; Hart, J.; Wennberg, A.K.; Gadek, J.E. Enteral nutrition with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants reduces alveolar inflammatory mediators and protein influx in patients with acute respiratory distress syndrome. Crit. Care Med., 2003, 31, 491-500.
115. Pontes-Arruda, A.; Aragão, A.M.; Albuquerque, J.D. Effects of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock. Crit. Care Med., 2006, 34, 2325-2333.
116. Pontes-Arruda, A.; Demichele, S.; Seth, A.; Singer, P. The use of an inflammation-modulating diet in patients with acute lung injury or acute respiratory distress syndrome: a meta-analysis of outcome data. J. Parenter. Enteral Nutr., 2008, 32, 596-605.
117. Kreymann, K.G.; Berger, M.M.; Deutz, N.E.; Hiesmayr, M.; Jolliet, P.; Kazandjiev, G.; Nitenberg, G.; van den Berghe, G.; Wernerman, J.; DGEM (German Society for Nutritional Medicine); Ebner, C.; Hartl, W.; Heymann, C.; Spies, C.; ESPEN (European Society for Parenteral and Enteral Nutrition). ESPEN Guidelines on Enteral Nutrition: Intensive care. Clin. Nutr., 2006, 25, 210-223.
118. Heyland, D.K.; Dhaliwal, R.; Drover, J.W.; Gramlich, L.; Dodek, P. Canadian Critical Care Clinical Practice Guidelines Committee. Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients. J. Parenter. Enteral Nutr., 2003, 27, 355-373.
119. ASPEN Board of Directors and the Clinical Guidelines Task Force. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. J. Parenter. Enteral Nutr., 2002, 26, 1SA-138SA.
120. Adhikari, N.; Burns, K.E.; Meade, M.O. Pharmacologic therapies for adults with acute lung injury and acute respiratory distress syndrome. Cochrane Database Syst. Rev., 2004, 4, 004477.
121. Heyland, D.K.; Samis, A. Does immunonutrition in patients with sepsis do more harm than good? Intensive Care Med., 2003, 29, 669-671.
122. The EDEN-Omega Study, ClinicalTrials.gov Identifier: NCT00609180.
123. A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI), ClinicalTrials.gov Identifier: NCT00351533
124. Rivers, J.P.; Hassam, A.G. Defective essential-fatty-acid metabolism in cystic fibrosis. Lancet, 1975, 2, 642-643.
125. Aldámiz-Echevarría, L.; Prieto, J.A.; Andrade, F.; Elorz, J.; Sojo, A.; Lage, S.; Sanjurjo, P.; Vázquez, C.; Rodríguez-Soriano, J. Persistence of essential fatty acid deficiency in cystic fibrosis despite nutritional therapy. Pediatr. Res., 2009, 66, 585-589.
126. Carlstedt-Duke, J.; Brönnegård, M.; Strandvik, B. Pathological regulation of arachidonic acid release in cystic fibrosis: the putative basic defect. Proc. Natl. Acad. Sci. U.S.A., 1986, 83, 9202-9206.
127. Freedman, S.D.; Blanco, P.G.; Zaman, M.M.; Shea, J.C.; Ollero, M.; Hopper, I.K.; Weed, D.A.; Gelrud, A.; Regan, M.M.; Laposata, M.; Alvarez, J.G.; O'Sullivan, B.P. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N. Engl. J. Med., 2004, 350, 560-569.
128. Bhura-Bandali, F.N.; Suh, M.; Man, S.F.; Clandinin, M.T. The deltaF508 mutation in the cystic fibrosis transmembrane conductance regulator alters control of essential fatty acid utilization in epithelial cells. J. Nutr., 2000, 130, 2870-2875.
129. Kang, J.X.; Man, S.F.; Brown, N.E.; Labrecque, P.A.; Clandinin, M.T. The chloride channel blocker anthracene 9-carboxylate inhibits fatty acid incorporation into phospholipid in cultured human airway epithelial cells. Biochem. J., 1992, 285, 725-729.
130. Strandvik, B. Fatty acid metabolism in cystic fibrosis. N. Engl. J. Med., 2004, 350, 605-607.
131. Miele, L.; Cordella-Miele, E.; Xing, M.; Frizzell, R.; Mukherjee, A.B. Cystic fibrosis gene mutation (deltaF508) is associated with an intrinsic abnormality in Ca2+-induced arachidonic acid release by epithelial cells. DNA Cell Biol., 1997, 16, 749-759.
132. Chase, H.P.; Dupont, J. Abnormal levels of prostaglandins and fatty acids in blood of children with cystic fibrosis. Lancet, 1978, 2, 236-238.
133. Strandvik, B.; Svensson, E.; Seyberth, H.W. Prostanoid biosynthesis in patients with cystic fibrosis. Prostaglandins Leukot. Essent. Fatty Acids, 1996, 55, 419-425.
134. Walkowiak, J.; Wilczynski, M.; Boleslawska, I.; Krawczynski, M.; Korzon, M.; Przyslawski, J. The predominance of omega-6 polyunsaturated fatty acids in cystic fibrosis despite low arachidonic acid levels. Acta Paediatr., 2003, 92, 1354-1355.
135. Keicher, U.; Koletzko, B.; Reinhardt, D. Omega-3 fatty acids suppress the enhanced production of 5-lipoxygenase products from polymorph neutrophil granulocytes in cystic fibrosis. Eur. J. Clin. Invest., 1995, 25, 915-919.
136. Ollero, M.; Laposata, M.; Zaman, M.M.; Blanco, P.G.; Andersson, C.; Zeind, J.; Urman, Y.; Kent, G.; Alvarez, J.G.; Freedman, S.D. Evidence of increased flux to n-6 docosapentaenoic acid in phospholipids of pancreas from cftr-/-knockout mice. Metabolism, 2006, 55, 1192-1200.
137. Freedman, S.D.; Katz, M.H.; Parker, E.M.; Laposata, M.; Urman, M.Y.; Alvarez, J.G. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr(-/-) mice. Proc. Natl. Acad. Sci. U.S.A., 1999, 96, 13995-14000.
138. Freedman, S.D.; Weinstein, D.; Blanco, P.G.; Martinez-Clark, P.; Urman, S.; Zaman, M.; Morrow, J.D.; Alvarez, J.G. Characterization of LPS-induced lung inflammation in cftr-/-mice and the effect of docosahexaenoic acid. J. Appl. Physiol., 2002, 92, 2169-2176.
139. Beharry, S.; Ackerley, C.; Corey, M.; Kent, G.; Heng, Y.M.; Christensen, H.; Luk, C.; Yantiss, R.K.; Nasser, I.A.; Zaman, M.; Freedman, S.D.; Durie, P.R. Long-term docosahexaenoic acid therapy in a congenic murine model of cystic fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol., 2007, 292, G839-G848.
140. Mimoun, M.; Coste, T.C.; Lebacq, J.; Lebecque, P.; Wallemacq, P.; Leal, T.; Armand, M. Increased tissue arachidonic acid and reduced linoleic acid in a mouse model of cystic fibrosis are reversed by supplemental glycerophospholipids enriched in docosahexaenoic acid. J. Nutr., 2009, 139, 2358-2364.
141. Lloyd-Still, J.D.; Powers, C.A.; Hoffman, D.R.; Boyd-Trull, K.; Lester, L.A.; Benisek, D.C.; Arterburn, L.M. Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study. Nutrition, 2006, 22, 36-46.
142. Jumpsen, J.A.; Brown, N.E.; Thomson, A.B.; Paul Man, S.F.; Goh, Y.K.; Ma, D.; Clandinin, M.T. Fatty acids in blood and intestine following docosahexaenoic acid supplementation in adults with cystic fibrosis. J. Cyst. Fibros., 2006, 5, 77-84.
143. Van Biervliet, S.; Devos, M.; Delhaye, T.; Van Biervliet, J.P.; Robberecht, E.; Christophe, A. Oral DHA supplementation in DeltaF508 homozygous cystic fibrosis patients. Prostaglandins Leukot. Essent. Fatty Acids, 2008, 78, 109-115.
144. Katz, D.P.; Manner, T.; Furst, P.; Askanazi, J. The use of an intravenous fish oil emulsion enriched with omega-3 fatty acids in patients with cystic fibrosis. Nutrition, 1996, 12, 334-339.
145. Christophe, A.; Robberecht, E.; De Baets, F.; Franckx, H. Increase of long chain omega-3 fatty acids in the major serum lipid classes of patients with cystic fibrosis. Ann. Nutr. Metab., 1992, 36, 304-312.
146. Henderson, W.R. Jr.; Astley, S.J.; McCready, M.M.; Kushmerick, P.; Casey, S.; Becker, J.W.; Ramsey, B.W. Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects. J. Pediatr., 1994, 124, 400-408.
147. Clandinin, M.T.; Zuberbuhler, P.; Brown, N.E.; Kielo, E.S.; Goh, Y.K. Fatty acid pool size in plasma lipoprotein fractions of cystic fibrosis patients. Am. J. Clin. Nutr., 1995, 62,1268-1275.
148. Panchaud, A.; Sauty, A.; Kernen, Y.; Decosterd, L.A.; Buclin, T.; Boulat, O.; Hug, C.; Pilet, M.; Roulet, M. Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: a randomized, crossover placebo-controlled trial. Clin. Nutr., 2006, 25, 418-427.
149. De Vizia, B.; Raia, V.; Spano, C.; Pavlidis, C.; Coruzzo, A.; Alessio, M. Effect of an 8-month treatment with omega-3 fatty acids (eicosapentaenoic and docosahexaenoic) in patients with cystic fibrosis. J. Parenter. Enteral Nutr., 2003, 27, 52-57.
150. Lawrence, R.; Sorrell, T. Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet, 1993, 342, 465-469.
151. Kurlandsky, L.E.; Bennink, M.R.; Webb, P.M.; Ulrich, P.J.; Baer, L.J. The absorption and effect of dietary supplementation with omega-3 fatty acids on serum leukotriene B4 in patients with cystic fibrosis. Pediatr. Pulmonol., 1994, 18, 211-217.
152. McKarney, C.; Everard, M.; N'Diaye, T. Omega-3 fatty acids (from fish oils) for cystic fibrosis. Cochrane Database Syst Rev., 2007, 4, CD002201.
153. Horrobin, D.F. Low prevalences of coronary heart disease (CHD), psoriasis, asthma and rheumatoid arthritis in Eskimos: are they caused by high dietary intake of eicosapentaenoic acid (EPA), a genetic variation of essential fatty acid (EFA) metabolism or a combination of both? Med. Hypotheses, 1987, 22, 421-428.
154. Black, P.N.; Sharpe, S. Dietary fat and asthma: is there a connection? Eur. Respir. J., 1997, 10, 6-12.
155. Wong, K.W. Clinical efficacy of n-3 fatty acid supplementation in patients with asthma. J. Am. Diet. Assoc., 2005, 105, 98-105.
156. Hallstrand, T.S.; Henderson, W.R.Jr. An update on the role of leukotrienes in asthma. Curr. Opin. Allergy Clin. Immunol., 2010, 10, 60-66.
157. Payan, D.G.; Wong, M.Y.; Chernov-Rogan, T.; Valone, F.H.; Pickett, W.C.; Blake, V.A.; Gold, W.M.; Goetzl, E.J. Alterations in human leukocyte function induced by ingestion of eicosapentaenoic acid. J. Clin. Immunol., 1986, 6, 402-410.
158. Hisada, T.; Ishizuka, T.; Aoki, H.; Mori, M. Resolvin E1 as a novel agent for the treatment of asthma. Expert Opin. Ther. Targets, 2009, 13, 513-522.
159. Devereux, G. Session 1: Allergic disease: Nutrition as a potential determinant of asthma. Proc. Nutr. Soc., 2010, 69, 1-10.
160. Prescott, S.L.; Calder, P.C. N-3 polyunsaturated fatty acids and allergic disease. Curr. Opin. Clin. Nutr. Metab. Care, 2004, 7, 123-129.
161. Thien, F.C.K.; De Luca, S.; Woods, R.K.; Abramson, M.J. Dietary marine fatty acids (fish oil) for asthma in adults and children. Cochrane Database Syst. Rev., 2002, 2, CD001283.
162. Schachter, H.; Reisman, J.; Tran, K.; Dales, B.; Kourad, K.; Barnes, D.; Sampson, M.; Morrison, A.; Gaboury, I.; Blackman, J. Health Effects of Omega-3 Fatty Acids on Asthma. Evidence Report/Technology Assessment No. 91 (Prepared by University of Ottawa Evidence-based Practice Center under Contract No. 290-02-0021). AHRQ Publication No. 04-E013-2. Rockville, MD: Agency for Healthcare Research and Quality, 2004.
163. Mickleborough, T.D.; Rundell, K.W. Dietary polyunsaturated fatty acids in asthma-and exercise-induced bronchoconstriction. Eur. J. Clin. Nutr., 2005, 59, 1335-1346.
164. McKeever, T.M.; Britton, J. Diet and asthma. Am. J. Respir. Crit. Care Med., 2004, 170, 725-729.
165. Mickleborough, T.D. Dietary omega-3 polyunsaturated fatty acid supplementation and airway hyperresponsiveness in asthma. J. Asthma, 2005, 42, 305-314.
166. Reisman, J.; Schachter, H.M.; Dales, R.E.; Tran, K.; Kourad, K.; Barnes, D.; Sampson, M.; Morrison, A.; Gaboury, I.; Blackman, J. Treating asthma with omega-3 fatty acids: where is the evidence? A systematic review. BMC Complement. Altern. Med., 2006, 6, 26.
167. Anandan, C.; Nurmatov, U.; Sheikh, A. Omega 3 and 6 oils for primary prevention of allergic disease: systematic review and meta-analysis. Allergy, 2009, 64, 840-848.
168. Devereux, G.; Seaton, A. Diet as a risk factor for atopy and asthma. J. Allergy Clin. Immunol., 2005, 115, 1109-1117.
169. Blümer, N.; Renz, H. Consumption of omega3-fatty acids during perinatal life: role in immuno-modulation and allergy prevention. J. Perinat. Med., 2007, 35, S12-S18.
170. Devereux, G. Early life events in asthma--diet. Pediatr. Pulmonol., 2007, 42, 663-673.
171. Gold, D.R.; Willwerth, B.M.; Tantisira, K.G.; Finn, P.W.; Schaub, B.; Perkins, D.L.; Tzianabos, A.; Ly, N.P.; Schroeter, C.; Gibbons, F.; Campos, H.; Oken, E.; Gillman, M.W.; Palmer, L.J.; Ryan, L.M.; Weiss, S.T. Associations of cord blood fatty acids with lymphocyte proliferation, IL-13, and IFN-gamma. J. Allergy Clin. Immunol., 2006, 117, 931-938.
172. Dunstan, J.A.; Mori, T.A.; Barden, A.; Beilin, L.J.; Taylor, A.L.; Holt, P.G.; Prescott, S.L. Fish oil supplementation in pregnancy modifies neonatal allergen-specific immune responses and clinical outcomes in infants at high risk of atopy: a randomized, controlled trial. J. Allergy Clin. Immunol., 2003, 112, 1178-1184.
173. Prescott, S.L.; Macaubas, C.; Smallacombe, T.; Holt, B.J.; Sly, P.D.; Holt, P.G. Development of allergen-specific T-cell memory in atopic and normal children. Lancet, 1999, 353, 196-200.
174. Calder, P.C.; Yaqoob, P.; Thies, F.; Wallace, F.A.; Miles, E.A. Fatty acids and lymphocyte functions. Br. J. Nutr., 2002, 87, S31-S48.
175. Kennedy, J.I. Jr.; Chandler, D.B.; Fulmer, J.D.; Wert, M.B.; Grizzle, W.E. Dietary fish oil inhibits bleomycin-induced pulmonary fibrosis in the rat. Exp. Lung Res., 1989, 15, 315-329.
176. Baybutt, R.C.; Rosales, C.; Brady, H.; Molteni, A. Dietary fish oil protects against lung and liver inflammation and fibrosis in monocrotaline treated rats. Toxicology, 2002, 175, 1-13.
177. Karmiol, S.; Remick, D.G.; Kunkel, S.L.; Phan, S.H. Regulation of rat pulmonary endothelial cell interleukin-6 production by bleomycin: effects of cellular fatty acid composition. Am. J. Respir. Cell. Mol. Biol., 1993, 9, 628-636.
178. Silva, L.P.; Lemos, A.P.; Curi, R.; Azevedo, R.B. Effects of fish oil treatment on bleomycin-induced pulmonary fibrosis in mice. Cell. Biochem. Funct., 2006, 24, 387-396.
179. Iwai, K.; Mori, T.; Yamada, N.; Yamaguchi, M.; Hosoda, Y. Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. Am. J. Respir. Crit. Care Med., 1994, 150, 670-675.
180. Miyake, Y.; Sasaki, S.; Yokoyama, T.; Chida, K.; Azuma, A.; Suda, T.; Kudoh, S.; Sakamoto, N.; Okamoto, K.; Kobashi, G.; Washio, M.; Inaba, Y.; Tanaka, H.; Japan Idiopathic Pulmonary Fibrosis Study Group. Dietary fat and meat intake and idiopathic pulmonary fibrosis: a case-control study in Japan. Int. J. Tuberc. Lung Dis., 2006, 10, 333-339.
181. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M.J. Cancer statistics, 2009. CA Cancer J. Clin., 2009, 59, 225-249.
182. Spira, A.; Ettinger, D.S. Multidisciplinary management of lung cancer. N. Engl. J. Med., 2004, 350, 379-392.
183. Welch, H.G.; Schwartz, L.M.; Woloshin, S. Are increasing 5-year survival rates evidence of success against cancer? JAMA, 2000, 283, 2975-2978.
184. Egleston, B.L.; Meireles, S.I.; Flieder, D.B.; Clapper, M.L. Population-based trends in lung cancer incidence in women. Semin. Oncol., 2009, 36, 506-515.
185. Scagliotti, G.V.; Longo, M.; Novello, S. Nonsmall cell lung cancer in never smokers. Curr. Opin. Oncol., 2009, 21, 99-104.
186. Wakelee, H.A.; Chang, E.T.; Gomez, S.L.; Keegan, T.H.; Feskanich, D.; Clarke, C.A.; Holmberg, L.; Yong, L.C.; Kolonel, L.N.; Gould, M.K.; West, D.W. Lung cancer incidence in never smokers. J. Clin. Oncol., 2007, 25, 472-478.
187. Schwartz, A.G.; Prysak, G.M.; Bock, C.H.; Cote, M.L. The molecular epidemiology of lung cancer. Carcinogenesis, 2007, 28, 507-518.
188. Herbst, R.S.; Heymach, J.V.; Lippman, S.M. Lung cancer. N. Engl. J. Med., 2008, 359, 1367-1380.
189. Maehle, L.; Lystad, E.; Eilertsen, E.; Einarsdottír, E.; Høstmark, A.T.; Haugen, A. Growth of human lung adenocarcinoma in nude mice is influenced by various types of dietary fat and vitamin E. Anticancer Res., 1999, 19, 1649-1655.
190. Hardman, W.E.; Moyer, M.P.; Cameron, I.L. Dietary fish oil sensitizes A549 lung xenografts to doxorubicin chemotherapy. Cancer Lett., 2000, 151, 145-151.
191. de Bravo, M.G.; de Antueno, R.J.; Toledo, J.; De Tomás, M.E.; Mercuri, O.F.; Quintans, C. Effects of an eicosapentaenoic and docosahexaenoic acid concentrate on a human lung carcinoma grown in nude mice. Lipids, 1991, 26, 866-870.
192. Toriyama-Baba, H.; Iigo, M.; Asamoto, M.; Iwahori, Y.; Park, C.B.; Han, B.S.; Takasuka, N.; Kakizoe, T.; Ishikawa, C.; Yazawa, K.; Araki, E.; Tsuda H. Organotropic chemopreventive effects of n-3 unsaturated fatty acids in a rat multi-organ carcinogenesis model. Jpn. J. Cancer Res., 2001, 92, 1175-1183.
193. Bradley, M.O.; Swindell, C.S.; Anthony, F.H.; Witman, P.A.; Devanesan, P.; Webb, N.L.; Baker, S.D.; Wolff, A.C.; Donehower, R.C. Tumor targeting by conjugation of DHA to paclitaxel. J. Control Release, 2001, 74, 233-236.
194. Wang, Y.; Li, L.; Jiang, W.; Larrick, J.W. Synthesis and evaluation of a DHA and 10-hydroxycamptothecin conjugate. Bioorg. Med. Chem., 2005, 13, 5592-5599.
195. Zijlstra, J.G.; de Vries, E.G.; Muskiet, F.A.; Martini, I.A.; Timmer-Bosscha, H.; Mulder, N.H. Influence of docosahexaenoic acid in vitro on intracellular adriamycin concentration in lymphocytes and human adriamycin-sensitive and -resistant small-cell lung cancer cell lines, and on cytotoxicity in the tumor cell lines. Int. J. Cancer, 1987, 40, 850-856.
196. Rudra, P.K.; Krokan, H.E. Cell-specific enhancement of doxorubicin toxicity in human tumour cells by docosahexaenoic acid. Anticancer Res., 2001, 21, 29-38.
197. Timmer-Bosscha, H.; Hospers, G.A.; Meijer, C.; Mulder, N.H.; Muskiet, F.A.; Martini, I.A.; Uges, D.R.; de Vries, E.G. Influence of docosahexaenoic acid on cisplatin resistance in a human small cell lung carcinoma cell line. J. Natl. Cancer Inst., 1989, 81, 1069-1075.
198. Rudra, P.K.; Krokan, H.E. Acrolein cytotoxicity and glutathione depletion in n-3 fatty acid sensitive-and resistant human tumor cells. Anticancer Res., 1999, 19, 461-469.
199. Schønberg, S.A.; Skorpen, F. Paracetamol counteracts docosahexaenoic acid-induced growth inhibition of A-427 lung carcinoma cells and enhances tumor cell proliferation in vitro. Anticancer Res., 1997, 17, 2443-2448.
200. Michiels, C.; Raes, M.; Toussaint, O.; Remacle, J. Importance of Se-glutathione peroxidase, catalase, and Cu/Zn-SOD for cell survival against oxidative stress. Free Radic. Biol. Med., 1994, 17, 235-248.
201. Trombetta, A.; Maggiora, M.; Martinasso, G.; Cotogni, P.; Canuto, R.A.; Muzio, G. Arachidonic and docosahexaenoic acids reduce the growth of A549 human lung-tumor cells increasing lipid peroxidation and PPARs. Chem. Biol. Interact., 2007, 165, 239-250.
202. de Antueno, R.J.; de Bravo, M.G.; Toledo, J.; Mercuri, O.; De Tomás, M.E. In vitro effect of eicosapentaenoic and docosahex-aenoic acids on prostaglandin E2 synthesis in a human lung carcinoma. Biochem. Int., 1989, 19, 489-496.
203. Yang, P.; Chan, D.; Felix, E.; Cartwright, C.; Menter, D.G.; Madden, T.; Klein, R.D.; Fischer, S.M.; Newman, R.A. Formation and antiproliferative effect of prostaglandin E(3) from eicosapentaenoic acid in human lung cancer cells. J. Lipid Res., 2004, 45, 1030-1039.
204. Harris, R.E. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology, 2009, 17, 55-67.
205. Harris, R.E.; Beebe-Donk, J.; Alshafie, G.A. Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study. Int. J. Biol. Sci., 2007, 3, 328-334.
206. Calviello, G.; Resci, F.; Serini, S.; Piccioni, E.; Toesca, A.; Boninsegna, A.; Monego, G.; Ranelletti, F.O.; Palozza, P. Docosahexaenoic acid induces proteasome-dependent degradation of betacatenin, down-regulation of survivin and apoptosis in human colorectal cancer cells not expressing COX-2. Carcinogenesis, 2007, 28, 1202-1209.
207. Lim, K.; Han, C.; Xu, L.; Isse, K.; Demetris, A.J.; Wu, T. Cyclooxygenase-2-derived prostaglandin E2 activates beta-catenin in human cholangiocarcinoma cells: evidence for inhibition of these signaling pathways by omega-3 polyunsaturated fatty acids. Cancer Res., 2008, 68, 553-560.
208. Calviello, G.; Di Nicuolo, F.; Gragnoli, S.; Piccioni, E.; Serini, S.; Maggiano, N.; Tringali, G.; Navarra, P.; Ranelletti, F.O.; Palozza, P. n-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and -2 and HIF1alpha induction pathway. Carcinogenesis, 2004, 25, 2303-2310.
209. Trifan, O.C.; Hla, T. Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J. Cell. Mol. Med., 2003, 7, 207-222.
210. Lim, K.; Wu, T. -3 pufas and other cancers. In: Dietary omega-3 polyunsaturated fatty acids and cancer (Series: Diet and Cancer), G.Calviello and S. Serini Eds,: Springer Science+Business Media B.V., 2010; vol. 1, pp. 191-218.
211. Backlund, M.G.; Mann, J.R.; Holla, V.R.; Buchanan, F.G.; Tai, H.H.; Musiek, E.S.; Milne, G.L.; Katkuri, S.; DuBois, R.N. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J. Biol. Chem., 2005, 280, 3217-3223.
212. Myung, S.J.; Rerko, R.; Yan, M.; Platzer, P.; Guda, K.; Dotson, A.; Lawrence, E.; Dannenberg, A.J.; Lovgren, A.K.; Luo, G.; Pretlow, T.P.; Newman, R.A.; Willis, J.; Dawson, D.; Markowitz, S.D. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc. Natl. Acad. Sci. U.S.A., 2006, 103, 12098-12102.
213. Tong, M.; Ding, Y.; Tai, H.H. Reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells. Carcinogenesis, 2006, 27, 2170-2179.
214. Serini, S.; Trombino, S.; Oliva, F.; Piccioni, E.; Monego, G.; Resci, F.; Boninsegna, A.; Picci, N.; Ranelletti, F.O.; Calviello, G. Docosahexaenoic acid induces apoptosis in lung cancer cells by increasing MKP-1 and down-regulating p-ERK1/2 and p-p38 expression. Apoptosis, 2008, 13, 1172-1183.
215. Vicent, S.; Garayoa, M.; López-Picazo, J.M.; Lozano, M.D.; Toledo, G.; Thunnissen, F.B.; Manzano, R.G.; Montuenga, L.M. Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of out-come in patients. Clin. Cancer Res., 2004, 10, 3639-3649.
216. Liu, C.; Russell, R.M.; Wang, X.D. Low dose beta-carotene supplementation of ferrets attenuates smoke-induced lung phosphorylation of JNK, p38 MAPK, and p53 proteins. J. Nutr., 2004, 134, 2705-2710.
217. Xia, S.H.; Wang, J.; Kang, J.X. Decreased n-6/n-3 fatty acid ratio reduces the invasive potential of human lung cancer cells by down-regulation of cell adhesion/invasion-related genes. Carcinogenesis, 2005, 26, 779-784.
218. Mernitz, H.; Lian, F.; Smith, D.E.; Meydani, S.N.; Wang, X.D. Fish oil supplementation inhibits NNK-induced lung carcinogenesis in the A/J mouse. Nutr. Cancer, 2009, 61, 663-669.
219. Fürstenberger, G.; Krieg, P.; Müller-Decker, K.; Habenicht, A.J. What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis? Int. J. Cancer, 2006, 119, 2247-2254.
220. Goto, K.; Tanaka, Y.; Matsumoto, Y.; Ueoka, R. Induction of apoptosis of human tumor cells by hybrid liposomes including docosahexaenoic acid. Bioorg. Med. Chem. Lett., 2008, 18, 1880-1883.
221. Tanaka, Y.; Goto K, Matsumoto Y, Ueoka R. Remarkably high inhibitory effects of docosahexaenoic acid incorporated into hybrid liposomes on the growth of tumor cells along with apoptosis. Int. J. Pharm., 2008, 359, 264-271.
222. Koo, L.C. Dietary habits and lung cancer risk among Chinese females in Hong Kong who never smoked. Nutr. Cancer, 1988, 11, 155-172.
223. Pierce, R.J.; Kune, G.A.; Kune, S.; Watson, L.F.; Field, B.; Merenstein D, Hayes A, Irving LB. Dietary and alcohol intake, smoking pattern, occupational risk, and family history in lung cancer patients: results of a case-control study in males. Nutr. Cancer, 1989, 12, 237-248.
224. Veierød, M.B.; Laake, P.; Thelle, D.S. Dietary fat intake and risk of lung cancer: a prospective study of 51,452 Norwegian men and women. Eur. J. Cancer Prev., 1997, 6, 540-549.
225. Takezaki, T.; Hirose, K.; Inoue, M.; Hamajima, N.; Yatabe, Y.; Mitsudomi, T.; Sugiura, T.; Kuroishi, T.; Tajima, K. Dietary factors and lung cancer risk in Japanese: with special reference to fish consumption and adenocarcinomas. Br. J. Cancer, 2001, 84, 1199-1206.
226. Nyberg, F.; Agrenius, V.; Svartengren, K.; Svensson, C.; Pershagen, G. Dietary factors and risk of lung cancer in never-smokers. Int. J. Cancer, 1998, 78, 430-436.
227. Skeie, G.; Braaten, T.; Hjartåker, A.; Brustad, M.; Lund, E. Cod liver oil, other dietary supplements and survival among cancer patients with solid tumours. Int. J. Cancer, 2009, 125, 1155-1160.
228. Zhang, J.; Temme, E.H.; Kesteloot, H. Fish consumption is inversely associated with male lung cancer mortality in countries with high levels of cigarette smoking or animal fat consumption. Int. J. Epidemiol., 2000, 29, 615-621.
229. Swanson, C.A.; Brown C.C.; Sinha R.; Kulldorff M.; Brownson R.C.; Alavanja M.C. Dietary fats and lung cancer risk among women: the Missouri Women's Health Study (United States), Cancer Causes Control, 1997, 8, 883-893.
230. Deneo-Pellegrini H.; De Stefani E.; Ronco A.; Mendilaharsu M.; Carzoglio J.C. Meat consumption and risk of lung cancer; a case-control study from Uruguay. Lung Cancer, 1996, 14, 195-205.
231. Dosil-Díaz, O.; Ruano-Ravina, A.; Gestal-Otero, J.J.; Barros-Dios, J.M. Meat and fish consumption and risk of lung cancer: A case-control study in Galicia, Spain. Cancer Lett., 2007, 252, 115-122.
232. Payne, M.; Ellis, P.; Dunlop, D.; Ranson, M.; Danson, S.; Schacter, L.; Talbot, D. DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial. J. Thorac. Oncol., 2006, 1, 984-990.
233. Cerchietti LC, Navigante AH, Castro MA. Effects of eicosapen-taenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. Nutr. Cancer, 2007, 59, 14-20.
234. Fearon, K.C.; Barber, M.D.; Moses, A.G.; Ahmedzai, S.H.; Taylor, G.S.; Tisdale, M.J.; Murray, G.D. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J. Clin. Oncol., 2006, 24, 3401-3407.
235. Grimble, R.F. Nutritional modulation of immune function. Proc. Nutr. Soc., 2001, 60, 389-397.
236. Markovic, O.; O'Reilly, G.; Fussell, H.M.; Turner, S.J.; Calder, P.C.; Howell, W.M.; Grimble, R.F. Role of single nucleotide polymorphisms of pro-inflammatory cytokine genes in the relationship between serum lipids and inflammatory parameters, and the lipid-lowering effect of fish oil in healthy males. Clin. Nutr., 2004, 23, 1084-1095.
237. Poole, E.M.; Bigler, J.; Whitton, J.; Sibert, J.G.; Kulmacz, R.J.; Potter, J.D.; Ulrich, C.M. Genetic variability in prostaglandin synthesis, fish intake and risk of colorectal polyps. Carcinogenesis, 2007, 28, 1259-1263.